|OraSure Technologies, Inc.|
220 East First Street
United States - Map
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its primary products include OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, HEMAgen BUFFY COAT, PrepITMAX, OMNIgeneGut, OMNIgene Sputum, Intercept, MICRO-PLATE DOA Assays, Intercept i2, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, the company manufactures and sells oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Further, it provides medical devices used for the removal of benign skin lesions by cryosurgery or freezing; various immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company sells its products to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.
|OraSure Technologies, Inc.’s ISS Governance QuickScore as of Jun 1, 2015 is 8. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Douglas A. Michels ,
Chief Exec. Officer, Pres and Director
|Mr. Ronald H. Spair ,
Chief Operating Officer, Chief Financial Officer and Director
|Mr. Mark L. Kuna ,
Principal Accounting Officer, Sr. VP of Fin., Controller and Assistant Sec.
|Mr. Jack E. Jerrett ,
Sr. VP, Gen. Counsel and Sec.
|Mr. Anthony Zezzo II,
Exec. VP of Marketing and Sales
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|